Panacos Company Description
Panacos Pharmaceuticals isn't looking for a panacea, just new treatments for HIV. The company is focused on the development of small molecule drugs that treat serious infectious diseases, including the virus that causes AIDS. Its lead antiviral candidate is bevirimat (also known as PA-457); the compound is a potential first-in-class treatment that blocks replication of the HIV virus. As it shepherds bevirimat through clinical trials, the company is also working on a second-generation version of the compound, as well as another anti-HIV therapy. Panacos shares ownership of the key patent underlying bevirimat with the University of North Carolina at Chapel Hill.
View the Comprehensive Company Description for Panacos
The Company Description provides a historical perspective of Panacos's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Panacos's evolution in the marketplace.
